Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangsu Recbio Technology Co., Ltd.
江蘇瑞科生物技術股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2179)

INSIDE INFORMATION ANNOUNCEMENT
COMPLETION OF FULL CIRCULATION OF H SHARES

This announcement is made by Jiangsu Recbio Technology Co., Ltd. (the "**Company**") pursuant to the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

References are made to the announcements of the Company dated May 21, 2025, January 30, 2026 and February 6, 2026 (the "**Announcements**") in relation to, among others, the Company's proposed participation in the H Share Full Circulation, the issuance of the filing notice by the CSRC in respect of the Company's H Share Full Circulation plan and the grant of listing approval by the Stock Exchange for the H Share Full Circulation plan of the Company. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

COMPLETION OF H SHARE FULL CIRCULATION

The Company is pleased to announce that the conversion of an aggregate of 141,953,489 unlisted shares into H Shares was completed on April 29, 2026, and the converted H Shares were listed on the Stock Exchange at 9:00 a.m. on April 30, 2026.

SHAREHOLDING STRUCTURE

The shareholding structure of the Company before and after completion of the Conversion and Listing is set out below:

	Before completion of the Conversion and Listing		After completion of the Conversion and Listing	
Class of shares	**Number of shares**	**Approximate percentage of the total number of issued shares of the Company**	**Number of shares**	**Approximate percentage of the total number of issued shares of the Company**
Domestic shares	297,937,013	47.59%	167,983,524	26.83%
Unlisted foreign shares	12,000,000	1.92%	0	0.00%
H Shares	316,138,689	50.50%	458,092,178	73.17%
Total	**626,075,702**	**100.00%**	**626,075,702**	**100.00%**

Note: Percentages have been rounded to the nearest two decimal places. Any discrepancy between the totals and the sum of the individual figures set out in this announcement is due to rounding.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Jiangsu Recbio Technology Co., Ltd.
Mr. XU Haoyu
Chairman

Jiangsu Province, the PRC, April 30, 2026

As at the date of this announcement, the Board comprises Mr. XU Haoyu as the chairman of the Board and a non-executive Director, Dr. LIU Yong, Ms. WANG Jing and Mr. WEI Qifang as executive Directors, Dr. WANG Ruwei, Dr. ZHANG Jiaxin, Dr. ZHOU Hongbin and Mr. HU Houwei as non-executive Directors, and Dr. XIA Lijun, Mr. LIANG Guodong, Professor GAO Feng and Professor YUEN Ming Fai as independent non-executive Directors.